Copyright © 2008 Bernard Gonik. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. Centers for Disease Control and Prevention, “Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease,” Morbidity And Mortality Weekly Report, vol. 47, no. RR19, pp. 1–39, 1998.
2. G. L. Armstrong, A. Wasley, E. P. Simard, G. M. McQuillan, W. L. Kuhnert, and M. J. Alter, “The prevalence of hepatitis C virus infection in the United States, 1999 through 2002,” Annals of Internal Medicine, vol. 144, no. 10, pp. 705–714, 2006.
3. National Institutes of Health (NIH), “Management of hepatitis C: 2002,” NIH Consensus State-of-the-Science Statement, 1–28, 2002, http://consensus.nih.gov/2002/2002HepatitisC2002116html.htm.
4. World Health Organization, “Hepatitis C. Epidemic and Pandemic Alert and Response,” 2002, http://www.who.int/csr/disease/hepatitis/whocdscsrlyo2003/en/index.html.
5. J. L. Dienstag and K. J. Isselbacher, “Acute viral hepatitis,” in Harrison's Principles of Internal Medicine, D. L. Kaspar, A. S. Fauci, D. L. Longo, E. Braunwald, S. L. Hauser, and J. L. Jameson, Eds., pp. 1822–1838, McGraw-Hill, New York, NY, USA, 16th edition, 2005.
6. M. J. Alter, L. B. Seeff, B. R. Bacon, D. L. Thomas, M. O. Rigsby, and A. M. Di Bisceglie, “Testing for hepatitis C virus infection should be routine for persons at increased risk for infection,” Annals of Internal Medicine, vol. 141, no. 9, pp. 715–717, 2004.
7. T. Poynard, P. Mathurin, C.-L. Lai, et al., “A comparison of fibrosis progression in chronic liver diseases,” Journal of Hepatology, vol. 38, no. 3, pp. 257–265, 2003. View at Publisher · View at Google Scholar
8. W. R. Kim, “The burden of hepatitis C in the United States,” Hepatology, vol. 36, no. 5B, pp. S30–S34, 2002. View at Publisher · View at Google Scholar · View at PubMed
9. L. E. Thorpe, L. J. Ouellet, R. Hershow, et al., “Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment,” American Journal of Epidemiology, vol. 155, no. 7, pp. 645–653, 2002. View at Publisher · View at Google Scholar
10. T. Diaz, D. C. Des Jarlais, D. Vlahov, et al., “Factors associated with prevalent hepatitis C: differences among young adult injection drug users in lower and upper Manhattan, New York City,” American Journal of Public Health, vol. 91, no. 1, pp. 23–30, 2001.
11. R. S. Garfein, D. Vlahov, N. Galai, M. C. Doherty, and K. E. Nelson, “Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses,” American Journal of Public Health, vol. 86, no. 5, pp. 655–661, 1996.
12. D. B. Strader, T. Wright, D. L. Thomas, and L. B. Seeff, “AASLD practice guideline. Diagnosis, management, and treatment of hepatitis C,” Hepatology, vol. 39, no. 4, pp. 1147–1171, 2004. View at Publisher · View at Google Scholar · View at PubMed
13. M. J. Alter, “Epidemiology of hepatitis C,” Hepatology, vol. 26, no. 3, supplement 1, pp. 62S–65S, 1997. View at Publisher · View at Google Scholar · View at PubMed
14. H. Meisel, A. Reip, B. Faltus, et al., “Transmission of hepatitis C virus to children and husbands by women infected with contaminated anti-D immunoglobulin,” The Lancet, vol. 345, no. 8959, pp. 1209–1211, 1995. View at Publisher · View at Google Scholar
15. C. Vandelli, F. Renzo, L. Romanò, et al., “Lack of evidence of sexual transmission of hepatitis C among monogamous couples: results of a 10-year prospective follow-up study,” The American Journal of Gastroenterology, vol. 99, no. 5, pp. 855–859, 2004. View at Publisher · View at Google Scholar · View at PubMed
16. J.-H. Kao, C.-J. Liu, P.-J. Chen, W. Chen, M.-Y. Lai, and D.-S. Chen, “Low incidence of hepatitis C virus transmission between spouses: a prospective study,” Journal of Gastroenterology and Hepatology, vol. 15, no. 4, pp. 391–395, 2000. View at Publisher · View at Google Scholar
17. G. Neumayr, A. Propst, H. Schwaighofer, G. Judmaier, and W. Vogel, “Lack of evidence for the heterosexual transmission of hepatitis C,” QJM, vol. 92, no. 9, pp. 505–508, 1999.
18. D. B. Brettler, P. M. Mannucci, A. Gringeri, et al., “The low risk of hepatitis C virus transmission among sexual partners of hepatitis C-infected hemophiliac males: an international multicenter study,” Blood, vol. 80, no. 2, pp. 540–545, 1992.
19. N. A. Terrault, “Sexual activity as a risk factor for hepatitis C,” Hepatology, vol. 36, no. 5B, pp. S99–S105, 2002. View at Publisher · View at Google Scholar · View at PubMed
20. M. A. Marx, K. G. Murugavel, P. M. Tarwater, et al., “Association of hepatitis C virus infection with sexual exposure in southern India,” Clinical Infectious Diseases, vol. 37, no. 4, pp. 514–520, 2003. View at Publisher · View at Google Scholar · View at PubMed
21. L. Gambotti, D. Batisse, N. Colin-de-Verdiere, et al., “Acute hepatitis C infection in HIV positive men who have sex with men in Paris, France, 2001–2004,” Euro Surveillance, vol. 10, no. 5, pp. 115–117, 2005.
22. C. Conry-Cantilena, M. VanRaden, J. Gibble, et al., “Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection,” The New England Journal of Medicine, vol. 334, no. 26, pp. 1691–1696, 1996. View at Publisher · View at Google Scholar
23. Centers for Disease Control and Prevention, K. A. Workowski, and S. M. Berman, “Vaccine preventable STDs. Sexually transmitted diseases treatment guidelines 2006,” Morbidity And Mortality Weekly Report, vol. 55, no. RR-11, pp. 69–76, 2006.
24. V. Puro, N. Petrosillo, and G. Ippolito, “Risk of hepatitis C seroconversion after occupational exposures in health care workers,” American Journal of Infection Control, vol. 23, no. 5, pp. 273–277, 1995. View at Publisher · View at Google Scholar
25. M. J. Alter, “Healthcare should not be a vehicle for transmission of hepatitis C virus,” Journal of Hepatology, vol. 48, no. 1, pp. 2–4, 2008. View at Publisher · View at Google Scholar · View at PubMed
26. Centers for Disease Control and Prevention, “Viral Hepatitis Transmission in Ambulatory Health Care Settings,” http://www.cdc.gov/ncidod/diseases/hepatitis/spotlights/ambulatory.htm.
27. M. J. Alter, “Epidemiology of hepatitis C in the West,” Seminars in Liver Disease, vol. 15, no. 1, pp. 5–14, 1995.
28. Z. Ackerman, E. Ackerman, and O. Paltiel, “Intrafamilial transmission of hepatitis C virus: a systematic review,” Journal of Viral Hepatitis, vol. 7, no. 2, pp. 93–103, 2000. View at Publisher · View at Google Scholar
29. J. L. Dienstag and J. G. McHutchison, “American gastroenterological association medical position statement on the management of hepatitis C,” Gastroenterology, vol. 130, no. 1, pp. 225–230, 2006. View at Publisher · View at Google Scholar · View at PubMed
30. T. Poynard, J. McHutchison, M. Manns, et al., “Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C,” Gastroenterology, vol. 122, no. 5, pp. 1303–1313, 2002. View at Publisher · View at Google Scholar
31. M. G. Swain, M.-Y. Lai, M. L. Shiffman, et al., “Durable sustained virological response after treatment with peginterferon $\alpha$-2a (PEGASYS$\circledR$) or in combination with ribavarin (COPEGUS$\circledR$): 5-year follow-up and the criteria of a cure,” Journal of Hepatology, vol. 46, p. S3, 2006. View at Publisher · View at Google Scholar
32. “PEGASYS$\circledR$ (peginterferon alfa-2a) package insert,” Hoffman-La Roche Inc, Nutley, NJ, USA, May 2007.
33. T. Poynard, P. Bedossa, and P. Opolon, “Natural history of liver fibrosis progression in patients with chronic hepatitis C,” The Lancet, vol. 349, no. 9055, pp. 825–832, 1997. View at Publisher · View at Google Scholar
34. T. Wong and S. S. Lee, “Hepatitis C: a review for primary care physicians,” Canadian Medical Association Journal, vol. 174, no. 5, pp. 649–659, 2006. View at Publisher · View at Google Scholar · View at PubMed
35. “Chronic hepatitis,” in The Merck Manual of Diagnosis and Therapy, M. H. Beers and R. Robert Berkow, Eds., Merck Research Laboratories, Whitehouse Station, NJ, USA, 2004.
36. G. Corrao and S. Aricò, “Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis,” Hepatology, vol. 27, no. 4, pp. 914–919, 1998. View at Publisher · View at Google Scholar · View at PubMed
37. J. Westin, L. M. Lagging, F. Spak, et al., “Moderate alcohol intake increases fibrosis progression in untreated patients with hepatitis C virus infection,” Journal of Viral Hepatitis, vol. 9, no. 3, pp. 235–241, 2002. View at Publisher · View at Google Scholar
38. S. Vento, T. Garofano, C. Renzini, et al., “Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C,” The New England Journal of Medicine, vol. 338, no. 5, pp. 286–290, 1998. View at Publisher · View at Google Scholar
39. C. M. Fuller, D. C. Ompad, S. Galea, Y. Wu, B. Koblin, and D. Vlahov, “Hepatitis C incidence—a comparison between injection and noninjection drug users in New York City,” Journal of Urban Health, vol. 81, no. 1, pp. 20–24, 2004. View at Publisher · View at Google Scholar · View at PubMed